Loading...
•
Jun 30, 2021
Esperion Q2 2021 Earnings Report
Esperion reported financial results for the second quarter ended June 30, 2021, with U.S. net product revenue growing 67% sequentially.
Key Takeaways
Esperion reported a net loss of $43.7 million for Q2 2021, with total revenues of $40.7 million. U.S. net product revenue grew 67% sequentially to $10.6 million, driven by increased demand and improved net price. The company is progressing with its CLEAR Outcomes study and expects complete MACE accumulation in 2H 2022.
Sheldon Koenig was appointed President and CEO.
JoAnne Micale Foody, MD, FACC, FAHA was appointed Chief Medical Officer.
U.S. net product revenue grew 67% sequentially.
Product positioning revisions positively impacted physician and payer engagement, increasing formulary adoption.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion provided financial outlook for the full year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income